| Metric | Q3 2026 | Q3 2025 |
|---|---|---|
| Revenue | 15.4 | 7.4 |
| Profit before tax | -7.9 | -16.7 |
| Net income | -7.9 | -16.2 |
| EPS (diluted, $ a share) | $-2.04 | $-5.30 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
| Revenue, year on year | +107.9% |
|---|---|
| Operating margin | -63.0% |
10-Q filed with the SEC, NYSE: PTHS. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
Pelthos Therapeutics Inc.: key numbers
- Share price
- $7.15Close, Nov 16
- Market cap
- $28.1M
- Shares outstanding
- 3.93MLatest SEC cover page
- Sector
- Life Sciences
- Industry
- Biological Products, (No Diagnostic Substances)SIC 2836
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from Pelthos Therapeutics Inc.
All →Pelthos Therapeutics Financial Results
Pelthos Therapeutics reported Q3 2026 financial results, highlighted by Zelsuvmi net product revenue of $15.2 million, a 114% increase year-over-year. The company also highlighted its pending transformative merger with Castle Creek Biosciences, which was announced in October 2026 to create a diversified biotechnology company focused on skin diseases.
“Zelsuvmi delivered another solid quarter, generating net product revenue of $15.2 million. Thousands of patients have already benefited from Zelsuvmi and we remain focused on driving Zelsuvmi growth and building on our success with the planned launches of Xepi® targeted in the first quarter of 2027 and Xeglyze® targeted in the third quarter of 2027.”
Scott Plesha, CEO of Pelthos
“In October, after the close of the third quarter, we took an important step in our pursuit of long-term value by announcing our agreement to combine with Castle Creek, a transaction that we believe will create a stronger, more diversified biotechnology company.”
Scott Plesha, CEO of Pelthos
Pelthos Therapeutics M&A Deal with Castle Creek Biosciences, Inc.
Pelthos Therapeutics has entered into a definitive agreement to acquire Castle Creek Biosciences in a merger transaction. Castle Creek stockholders will receive 5.2 million shares of Pelthos common stock plus potential milestone payments totaling up to $300 million tied to the clinical and commercial success of the D-Fi gene therapy franchise. The deal combines Pelthos' commercial dermatology infrastructure with Castle Creek's late-stage cell and gene therapy platform for rare skin diseases.
- Counterparty
- Castle Creek Biosciences, Inc.
Pelthos Therapeutics Insider Peter Greenleaf Sells $16.9K of Stock
Peter Greenleaf sold 797 shares of Pelthos Therapeutics Inc. at $21.17 a share, worth $16.9K in total on Oct 2, 2026. Shares held after the trade: 23,087 (-3.3%).
- Value
- $16.9K
- Shares
- 797
- Price
- $21.17
- Holding change
- -3.3%
- Trade date
- Oct 2, 2026
Pelthos Therapeutics Insider Ezra M. Friedberg Sells $11.6K of Stock
Ezra M. Friedberg sold 558 shares of Pelthos Therapeutics Inc. at $20.72 a share, worth $11.6K in total on Oct 2, 2026. Shares held after the trade: 80,484 (-0.7%).
- Value
- $11.6K
- Shares
- 558
- Price
- $20.72
- Holding change
- -0.7%
- Trade date
- Oct 2, 2026
Pelthos Therapeutics Insider Matthew Pauls Sells $16.5K of Stock
Matthew Pauls sold 786 shares of Pelthos Therapeutics Inc. at $21.00 a share, worth $16.5K in total on Oct 2, 2026. Shares held after the trade: 13,578 (-5.5%).
- Value
- $16.5K
- Shares
- 786
- Price
- $21.00
- Holding change
- -5.5%
- Trade date
- Oct 2, 2026
Pelthos Therapeutics Shareholder Meeting
Pelthos Therapeutics held its 2026 Annual Meeting of Stockholders where shareholders elected eight directors to serve until the 2027 meeting and ratified Grant Thornton LLP as the independent auditor for fiscal year 2026. Additionally, stockholders approved the 2026 Equity Incentive Plan, which replaces the company's previous 2023 plan.